Blog

With new variants of COVID-19 constantly emerging, the urgency to adapt and enhance our defensive strategies against the virus continues to grow. Pharmaceutical companies Pfizer, Moderna, and Novavax are at the forefront, gearing up to release their new booster shots designed to counter the XBB.1.5 version of the omicron strain. The U.S. FDA and CDC are expected to play crucial roles in determining their rollout and recommendations for administration. Our primary care doctors in Jupiter are here with everything you need to know about the anticipated booster shots.

What’s in the New Boosters?

The focal point in the development of these new boosters is the XBB.1.5 version of the omicron strain. While it is no longer the dominant strain in the U.S., it is anticipated that the new versions of the booster will offer strong protection against severe illness, an imperative as case numbers and hospitalizations are witnessing an uptick.

Who Will be Eligible?

As we stand on the verge of approvals and recommendations from the FDA and CDC, there is yet an official list of who will be eligible for these booster shots. Dr. Paul Offit, a member of the FDA panel reviewing the boosters, indicated that initial targets might be high-risk groups including individuals aged 75 and older, pregnant individuals, and those who are immunocompromised. However, the ultimate decision rests with the CDC’s advisory committee which is expected to meet soon to finalize the recommendations.

The Cost of Protection

For the first time since the onset of the pandemic, the federal government has stepped back from covering the cost of the COVID-19 vaccines. Pfizer and Moderna have priced their vaccines in the range of $110 to $130 per dose. Both companies have assured the provision of patient assistance programs to facilitate vaccine accessibility for individuals without coverage or who are underinsured.

The Affordable Care Act mandates insurers to cover the cost of many recommended vaccines, hence many individuals with private health insurance or public program coverage like Medicare or Medicaid are expected to incur no out-of-pocket expenses. The pricing strategy of Novavax remains under wraps as of now, with the Biden administration encouraging a “reasonable price” in a bid to uphold the citizens’ best interests.

What Lies Ahead

The big date circled in calendars is mid-September, with the CDC anticipating the release of these new vaccines around that time, following a string of approvals and recommendations from the FDA and the CDC’s advisory committee. The collective hope is for a smooth rollout and comprehensive coverage to brace against the surging cases and safeguard the most vulnerable in society.

As we wait for more detailed guidance from the health authorities, it is vital to stay informed and prepared. Whether or not you will be recommended for the booster, continuing to adhere to prevailing safety measures and getting vaccinated if you haven’t yet remains paramount. The ever-evolving situation demands vigilance and readiness from us all as we stand united in the fight against COVID-19.